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ABSTRACT                        Bacteriophages are speciﬁc infective agents of various bacteria. They can be 
divided into various groups according to their life cycle. The lytic phages kill their host cells 
and this property can be applied for selective elimination of pathogenic bacteria. The ﬁrst 
bacteriophage treatment was described one hundred years ago, and phage therapy had been 
extensively used till the Second World War. Upon appearance of antibiotics, the medical ap-
plication of phages retrograded in most parts of the world. In the last decades, owing to the 
costs of development of new antibiotics and rapid emergence of multidrug-resistant bacteria, 
this old approach was revitalized and phage-based treatment was legalized from the middle of 
the last decade. Here, we summarize the current knowledge on phage therapy, its advantages 
and potential drawbacks. The application of phages against plant pathogens, especially Erwinia 
amylovora is discussed. Moreover, the current status of phage therapy against food-borne, 
animal and human pathogens is also presented. Among these, special focus is set on phages of 
Staphylococcus aureus, Salmonella typhimurium and Listeria monocytogenes. Phage cocktails 
against L. monocytogenes and E. amylovora have been already commercialized.
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History of bacteriophage therapy 
Bacteriophages (phages) are viruses, which are obligate intra-
cellular parasites of bacteria. The total global population of 
tailed phages, being the most abundant organisms on Earth, 
is estimated in the order of 1031 viral particles (Waldor et al. 
2005). According to the 2014 release of Virus Taxonomy by 
the International Committee on Taxonomy of Viruses, seven 
orders were established: Caudovirales (3 families), Herpes-
virales (3 families), Legamenvirales (3 families), Mononega-
virales (3 families), Nidovirales (3 families), Picornavirales 
(3 families) and Tymovirales (3 families). Seventy-eight virus 
families could not be assigned to these orders (http://www.
ictvonline.org/virusTaxonomy.asp). The tailed phages consti-
tute the largest group, the order Caudovirales. On the basis 
of length and contractibility of the tails, it has three families: 
Myoviridae, Siphoviridae and Podoviridae. Bacteriophages 
can be divided into various groups according to their life cycle 
(Fig. 1); they can productively infect the host bacterium re-
sulting in more viruses or can get into a latent state when their 
genomes are integrated into the host cell DNA. In the latter 
case, the virus is multiplied with the host genome. During the 
productive infection, phages can lyse the cells or virions can 
be released without cell lysis (Waldor et al. 2005). The lytic 
phages are able to kill the target cells while the lysogenic/
temperate phages become part of the genome of the host 
cells and stay there for a time. Under special environmental 
conditions, the life cycle of these phages might switch to 
productive phase, the phage genome is cut off from the host 
DNA, packed into a protein shell and the mature phages lyse 
the cells. Phage therapy is simply destroying the pathogenic 
bacteria by their natural infecting agents, bacteriophages. 
For pathogen elimination, the most important viruses are the 
lytic phages. Lysogeny must be avoided since it can lead to 
unwished gene transfer. Consequently, the exclusively lytic 
phages can be considered as real biocontrol agents. Neverthe-
less, temperate phages can be often converted into obligately 
lytic ones.
The utilization of phages to destroy bacterial infections 
is nearly as old as the discovery of the bacteriophages. The 
English bacteriologist Frederick Twort published the ﬁrst ob-
servation of a transmissible bacterial lysing agent for Staphy-
lococcus (Twort 1915). In 1917, a French-Canadian microbi-
ologist, Felix d’Herelle discovered an invisible antagonist of 
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dysentery bacillus. A little bit later, Bruynoghe and Maisin 
(1921) applied bacteriophages to eliminate staphylococcal 
cells from skin, thus this work was the ﬁrst public applica-
tion of phages to treat infectious diseases. Phage therapy has 
been expanded in the 1920s-1940s for numerous pathogenic 
bacteria and at that time at least three commercial anti-staph-
ylococcal phage preparations were available on the market 
produced by Eli Lilly, E.R. Squibb and Sons and Swan-Myers 
(Straub and Applebaum 1933). Later, upon the emergence 
of broad-spectrum antibiotics, the application of phages was 
forfeited and the virus-related researches were directed into 
rather theoretical aspects in Western Europe. Nevertheless, 
in the Soviet Union (mainly in Georgia) and Poland, phage 
therapeutical treatments were continued and widely practiced, 
and both theoretical and applied projects on this topic were 
going on. Unfortunately, the articles focusing on phage-based 
biocontrol were published in Russian: therefore, they were 
not readily available/understandable for Western scientists. 
Moreover, these studies were not performed systematically, 
and in numerous cases they were not well-controlled. 
However, after a long latent period, owing to the emer-
gence of multidrug-resistant bacteria and the increasing cost/
time of development of new antibiotics and antimicrobial 
drugs, the interest was redirected towards phage therapy 
(Chanishvili 2012a, 2012b). 
Advantages and limitations of 
bacteriophages versus other approaches
The application of phages has numerous substantial advan-
tages (Villa and Veiga-Crespo 2010): 
1) phages can be easily propagated, moreover, they can 
be produced at the site of the potential application, at the site 
of infection; 
2) their production is fast and cheap;
3) bacteriophages are speciﬁc for their host cells, they 
do not destroy other beneﬁcial microbes in the normal mi-
crobiota; 
4) their application has minimal – if any – side effects; one 
of the most comprehensive human safety tests, performed by 
Delmont Laboratories, demonstrated only minor side effects 
in the patients after 12 years (Kutter and Sulakvelidze 2005). 
In that study, various administration techniques were applied 
and compared: the phages were introduced to humans intrana-
sally, topically, orally, subcutaneously and intravenously;
5) they are not, or just minimally allergenic – although, 
it was shown that numerous antibodies could interact with 
phages, very few of them could neutralize them (Kutter and 
Sulakvelidze 2005);
6) they can be introduced into the patients through dif-
Figure 1. Life cycles of bacteriophages. The therapeutically applicable phage life cycle is set in bold.
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ferent routes; 
7) their usage can be combined with a number of treat-
ments and drugs, including other phages, phage cocktails or 
antibiotics;
8) development of novel cocktails against resistant bacte-
ria is faster and cheaper than that of new antibiotics or other 
antimicrobials;
9) the application range of bacteriophages is much broader 
than that of antibiotics: they can be applied, e.g., as protective 
materials in food supplements, in milk industry, in pharma-
cology as eye drops, in toothpastes, in cleaning solutions 
(Villa and Veiga-Crespo 2010). The US Food and Drug Ad-
ministration (FDA) has approved bacteriophages as “gener-
ally recognized as safe” (GRAS) agents to control Listeria 
monocytogenes on ready-to-eat meat and poultry products 
(US FDA 2006).
In spite of the uncountable beneﬁcial properties of phage-
based biocontrol, the application of antibacterial phage 
therapy still faces challenges and problems to be solved: (i) 
the phages might have too narrow host range: on the one 
hand, the target speciﬁcity has advantages (see “point 3”), 
but on the other hand, the serotype speciﬁcity might reduce 
their effectivities, which is unwanted; (ii) safe propagation 
of phages speciﬁc for pathogenic strains should be solved 
on non-pathogenic host; (iii) standardized puriﬁcation of 
pathogen-free phages suitable for treatments; (iv) the poten-
tial immunogenicity of phages in the human body; (v) the 
pharmacokinetics of phage treatment, application of phages 
against encapsulated or internalized bacteria or biofilms 
(Hermoso et al. 2007). 
The release of various pro-inﬂammatory components, 
such as e.g., endotoxins and peptidoglycan from the lysed 
bacterium might also cause problems. In principle, these 
components could result in a septic shock and multiple organ 
failure (Nau and Eiffert 2002). Fortunately, many carefully 
performed experimental studies justiﬁed that there were no 
remarkable side effects after robust lysis of infecting bacte-
ria. Moreover, every treatment aiming to kill the pathogens 
might be accompanied by this risk, thus it is not speciﬁc for 
phage therapy.
In spite of the potential drawbacks, the phage-based 
biocontrol and bacteriophage therapy are very promising 
approaches, therefore, research studies and well-controlled 
applications in this ﬁeld are encouraged by international or-
ganizations. In the next sections, several examples for phages 
applicable against plant, animal and human pathogens are 
discussed. 
Phages against plant pathogens
Bacteriophages have been isolated and characterized against 
many plant pathogenic bacterial species, the most important 
ones being Agrobacterium tumefaciens, Erwinia amylovora, 
Pseudomonas syringae pv. tomato, Ralstonia solanacearum, 
Xanthomonas arboricola pv. juglandis, Xanthomonas arbori-
cola pv. pruni, Xanthomonas oryzae pv. oryzae, Xanthomonas 
campestris pv. vesicatoria (Stonier et al. 1967; Ghei et al. 
1968; Lin et al. 1994; Gill et al. 2003; Greer 2005; Bae et 
al. 2012; Dömötör et al. 2012; Romero-Suarez et al. 2012; 
Yamada 2013; Chae et al. 2014).
Application of bacteriophages against plant pathogenic 
bacteria as biopesticides opens possibilities for the control 
of devastating bacterial diseases, against which no effective 
measures exist. Therefore, besides the scientific impor-
tance, an economic interest also girdles around the results 
of characterization and application of phages infecting plant 
pathogenic bacteria. Application of phages as biopesticides 
has several unique features originating - at least partly - from 
the environment of usage.
The number of phages located in the soil is estimated to 
be 1.5 x 108 g soil, which is about 4% of the total bacterial 
population that could be found here (Ashelford et al. 2003). 
Phages on the ﬁeld face themselves with the unfavorable 
circumstances of the rhizosphere, which comprises the soil 
and the environment surrounding the roots of plants. The most 
factors which can negatively inﬂuence the disease control in 
the rhizosphere are summarized in the review of Jones et al. 
(2007). Phages can be trapped in bioﬁlms (Storey and Ashbolt 
2001), adsorbed to soil particles reversibly and inactivated 
by low pH present in the soil (Jones et al. 2007). The rate 
of diffusion through the soil matrix is low and changing, as 
it depends on the presence of free water (Jones et al. 2007). 
Physical objects can hinder phages to reach host bacteria. A 
serious problem is that a high number of host bacteria and 
infectious phages are needed in order to start a chain reaction 
of bacterial lysis (Jones et al. 2007).
The phyllosphere provides a harsh environment for bacte-
riophages, where they will be inactivated rapidly (Jones et al. 
2007). The most limiting factor is UV irradiation (Ignoffo and 
Garcia 1994), however, high and low pH, exposure to high 
temperature, desiccation and being washed away by rain can 
also seriously decrease the number of phages able to infect 
host bacteria (Civerolo and Keil 1969; Ignoffo et al. 1989; 
Ignoffo and Garcia 1992; Balogh et al. 2003). How a biope-
sticide can be applied under these unfavorable circumstances 
will be detailed on the example of E. amylovora phages.
E. amylovora, a Gram-negative bacterium, member of 
Enterobacteriaceae, is the causative agent of a devastating 
wilt disease - called ﬁre blight - of some rosaceous plants 
(van der Zwet and Beer 1995). Apple, pear and quince should 
be highlighted as being economically especially important 
among its host plants. The infection cycle begins in spring 
with elevation of temperature when E. amylovora colonizes 
open blossoms, multiplies and infect the trees through natural 
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openings (van der Zwet and Beer 1995). The bacterium over-
winters at the margin of cankers and becomes active again in 
the spring (van der Zwet and Beer 1995). Control of ﬁre blight 
is a hard challenge especially in countries where streptomycin 
is not registered. An alternative solution for the treatment of 
this disease is the application of bacteriophages.
Phages against E. amylovora were isolated mostly from 
the soil surrounding infected trees but a few isolates origi-
nated from infected aerial tissues (Erskine 1973; Ritchie and 
Klos 1977; Schnabel and Jones 2001; Gill et al. 2003; Born et 
al. 2011; Dömötör et al. 2012; Meczker et al. 2014; Yagubi et 
al. 2014; Lagonenko et al. 2015). E. amylovora phages were 
extensively characterized (Gill et al. 2003; Born et al. 2011; 
Dömötör et al. 2012; Born et al. 2014; Meczker et al. 2014; 
Yagubi et al. 2014; Lagonenko et al. 2015). All E. amylovora 
phages belong to Caudovirales with all three of its families 
(Podoviridae, Myoviridae and Siphoviridae) represented. 
Several phages have a narrow host range (Gill et al. 2003) 
but others are able to infect Pantoea agglomerans (Gill et al. 
2003) and other members of the Enterobacteriaceae family, 
as well (Kovács et al., unpublished results). Their genome 
sizes vary between 30 and 271 kb (Dömötör et al. 2012; 
Meczker et al. 2014; Yagubi et al. 2014; Lagonenko et al. 
2015). Plant and ﬁeld trials (Erskine 1973; Schnabel et al. 
1999; Svircev et al. 2010; Nagy et al. 2012) have shown the 
potential applicability of these phages against E. amylovora. 
Schnabel et al. (1999) registered a 37% decrease of fire 
blight symptoms in a ﬁeld study where a mixture of three 
phages was used to spray on a marked strain of E. amylovora. 
The success of several other trials (Ritchie and Klos 1977; 
Schnabel and Jones 2001) was limited due to the fact that the 
number of phage populations declined rapidly in the absence 
of the host pathogen because of unfavorable circumstances in 
the phyllosphere. Schnabel and Jones (2001) suggested ap-
plying a nonpathogenic (mutant) E. amylovora strain together 
with the administration of phages to maintain the number of 
the latter ones, however, this would be too risky due to the 
chance of reversion to a virulent phenotype. Svircev et al. 
(2010) advocated applying Pantoea agglomerans, a non-
pathogenic epiphyte abundant in fruit orchards, together with 
E. amylovora phages. A P. agglomerans strain which could 
be infected by many phages (32 from the tested 54) and can 
produce as high titer as >108 plaque-forming units (PFUs)/
ml of viruses was selected through a sequential process. The 
co-application of this saprophyte with E. amylovora phages 
can maintain a high level of viruses until the pathogenic host 
is present in the phyllosphere (Lehman 2007). 
Another possibility to protect phages against UV is the 
utilization of UV-protecting agents as adjuvants, as it was 
performed in the case of two patents (Hu P0700600 and Hu 
P1300407) applying a cocktail of extensively characterized 
phages together with the adjuvant. Based on successful au-
thority trials with this formulation (publication of results is in 
progress) a new phage-based pesticide has been authorized in 
Hungary since 2012. This is the ﬁrst anti-E. amylovora phage 
therapeutic product which was marketed in a country. This 
product has been applied on apple, pear and quince ﬁelds 
and user’s satisfaction was mainly positive. Negative results 
were partly connected with improper usage of the biopesti-
cide. The application of this product was difﬁcult because it 
had to be sprayed after sunset, three times during blooming, 
and contact with copper had to be avoided. Also freezing 
of phages had to be prevented, but the ﬂasks containing the 
active components should be kept cooled. In several cases, 
the water, which was used for the dilution of the pesticide, 
was polluted with heavy metals which decreased the number 
of infective viruses, as demonstrated during laboratory trials 
(Kovács, unpublished results).
An important question is whether phages can be taken up 
by the plants and can reach E. amylovora also inside the plant, 
or they can act only as contact agents. Preliminary results 
showed that phages can pass into the plants when sprayed 
into the phyllosphere and will be translocated towards the 
roots in apple seedlings (Kovács et al. 2012). More recently 
these results were supported by new trials and the possibility 
of phage uptake through the roots was also proved (Nagy et 
al. 2015). The severity of symptoms caused by E. amylovora 
decreased due to the penetrated and translocated phages in 
apple seedlings (Nagy et al. 2015). However, whether the 
fact that phages can enter the plants and will be translocated 
has any signiﬁcant anti-E. amylovora effect in the orchard, 
in the case of apple trees, should be clariﬁed. A further ques-
tion which should be elucidated is the mechanism of the 
uptake and systematic movement of bacteriophages, taken 
into consideration that the cell-to-cell movements of mac-
romolecular complexes and viruses are hindered by the size 
exclusion limit of plasmodesmata, which obviously would 
exclude bacteriophages. Plant viruses developed strategies 
(usually their genomes encode virus movement proteins) to 
overcome the barrier of plasmodesmata (Benitez-Alfonso et 
al. 2010), however, genes coding for similar proteins have not 
been found in the case of any sequenced genomes of phages 
infecting plant pathogenic bacteria. 
Two phage-therapeutic pesticides have been registered 
and marketed worldwide until now. The ﬁrst was registered 
by OmniLytics in the USA against Xanthomonas campestris 
pv. vesicatoria and Pseudomonas syringae pv. tomato, and the 
second one by Enviroinvest in Hungary against E. amylovora. 
The broad application of phage-based products in crop protec-
tion is seriously inﬂuenced by the registration procedure of 
these biopesticides. According to the legal regulations of the 
EU (1107/2009 EC), a bacteriophage cocktail which will be 
altered in only one of its components should be reregistered, 
which would need signiﬁcant time and capital investment. 
Taken into consideration that pathogenic host bacteria in the 
orchard may acquire resistance against the applied phage-
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based pesticide rapidly after the treatment (Jones et al. 2007), 
the need of changing the composition of phage cocktails is 
an important factor, which cannot be followed by the current 
registration process. It would be crucial to change the relevant 
rules in such sense that the need of characterization of phages 
prior on site application should be standardized and changing 
the phage composition of pesticides should be allowed.
Based on the data presented in this paper, application of 
bacteriophages is a promising tool for the control of plant 
pathogenic bacteria on the ﬁelds.
Phages against human/animal (food-borne) 
pathogens
Staphylococcus aureus and Pseudomonas 
aeruginosa
Bacteriophages have speciﬁc scientiﬁc interest in view of their 
ability to kill multidrug-resistant (MDR) bacteria without 
disturbing the normal microbiota (Gandham 2015). In hu-
man health care, S. aureus and P. aeruginosa belong to the 
most frequent MDR pathogens causing both nosocomial and 
community-acquired infections (Nordmann et al. 2007; WHO 
2012). The emergence of these MDR pathogens is increas-
ingly reported worldwide (Chastre 2008).
Bacterial infections are often difﬁcult to treat or untreat-
able and can be life-threatening. In humans, S. aureus can 
cause endocarditis, osteomyelitis, meningitis, pneumonia, 
septicemia and toxic shock syndrome (Lowy 1998). P. aerugi-
nosa is related to infections in humans mainly in predisposed 
immunocompromised patients due to chemotherapy, trans-
plantations and HIV-infection. It can cause respiratory tract, 
urinary tract, ear, eye and burn wound infections (Lyczak et 
al. 2000).
Phages against S. aureus and P. aeruginosa are wide-
spread and have been extensively studied (Hayashi and Na-
kayama 2004; Ceyssens and Lavigne 2010; Deghorain and 
Van Melderen 2012; Xia and Wolz 2014). They were ﬁrstly 
used for the typing of clinical isolates of these two bacterial 
species (Blair and Williams 1961; Wentworth 1963; Bergan 
1978).
All known S. aureus phages are double-stranded DNA 
phages belonging to the order Caudovirales (Deghorain and 
Van Melderen 2012; Xia and Wolz 2014). They can be fur-
ther classiﬁed into three major families based on tail types: 
Podoviridae (very short tail), Siphoviridae (long, non-contrac-
tile tail) and Myoviridae (long, contractile, double-sheathed 
tail). According to the genome size of S. aureus phages, three 
categories (which correlate with the morphological classiﬁca-
tion) can be established: podoviruses have the smallest ge-
nomes (16-18 kbp), siphoviruses show intermediate genome 
sizes (39-43 kbp) and myoviruses contain the largest ones 
(120-140 kbp) (Kwan et al. 2005).
The majority of the described P. aeruginosa-specific 
phages belong to the order Caudovirales. Representatives 
can be found in all three families of Caudovirales. Some P. 
aeruginosa phages have single-stranded DNA (ssDNA) or 
single-stranded RNA (ssRNA) and can be classiﬁed into the 
families Inoviridae or Leviviridae (Hayashi and Nakayama 
2004; Ceyssens and Lavigne 2010). In contrast to phages of 
S. aureus, the genome sizes of most P. aeruginosa-speciﬁc 
phages are uniformly distributed from 35 to 75 kbp (Kwan 
et al. 2006) with the exception of the large PhiKZ-like vi-
ruses which have genomes of 210 to 280 kbp (Krylov et al. 
2007).
The ﬁrst report on the medical application of phages was 
published by Bruynoghe and Maisin (1921). They treated skin 
disorders caused by S. aureus. Injection of staphylococcal 
phages resulted in improvement within 48 hours and reduc-
tion in pain, swelling and fever. Both S. aureus and P. aerugi-
nosa were among the most common targets of phage therapy 
and are still common today. Several companies in Europe and 
the USA (L’Oréal, Eli Lilly, Squibb & Sons, Parke-Davis, 
Swan-Myers Division of Abbott Laboratories) manufactured 
and sold therapeutic phage preparations (monophage, cocktail 
or phage lysate) against these pathogens (Straub and Ap-
plebaum 1933; Sulakvelidze et al. 2001).
A wide range of encouraging studies documented the ef-
ﬁcacy of speciﬁc phages or phage cocktails in both combined 
phage and antibiotic therapy and phage therapy alone. These 
early phage therapy trials established methods for the oral, 
subcutaneous, intramuscular and intravenous application of 
phage preparations. Phages have also been used in prophylac-
tic and sanitation experiments (Chanishvili et al. 2012b).
The most comprehensive English language report on 
phage therapy in humans was published by Slopek and 
co-workers (1987). They treated 550 patients suffering 
from infections with antibiotic-resistant Staphylococcus, 
Pseudomonas, Escherichia coli, Klebsiella, Salmonella and 
Streptococcus between 1981 and 1986. The success rate 
ranged from 75% to 100% depending on the bacterium. They 
observed signiﬁcant improvement in polymicrobial infection 
as well as in cases where antibiotic therapy was ineffective 
(Slopek et al. 1987).
The above-mentioned, encouraging case studies had some 
deﬁciencies, such as the lack of proper controls, the insuf-
ﬁcient purity of phage preparations or the small numbers of 
patients. This could be a reason why phage therapy is not 
used or accepted in most parts of the world. In the future, con-
trolled and regulated clinical investigations should be carried 
out to introduce phage therapy as a routine medical procedure. 
Phage preparations applied for human clinical trials or therapy 
must be carefully studied under various conditions to reduce 
many potential safety concerns. Identiﬁcation, morphology 
and biology of phages must be determined using such pro-
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cedures as electron microscopy (EM), host range analysis, 
restriction fragment length polymorphism (RFLP) and one 
step growth curve analysis. Only those fully sequenced and 
analyzed phages are appropriate for further use, for which the 
phage genome and proteome analysis demonstrate that the 
phages are really virulent (killing bacteria under all condi-
tions), their genomes do not encode toxins and other factors 
of pathogenicity and virulence and do not have the ability 
to participate in a process of horizontal gene transfer. Strin-
gent puriﬁcation of phage preparation is required to remove 
remaining uninfected cells, post-lysis bacterial ghosts and 
some other bacterial lysis products such as endotoxins. Ultra-
centrifugation, a series of ﬁltration steps, or various forms of 
chromatography can be involved in the puriﬁcation process. 
The elaborate quality control must include stability (shelf 
life), determination of pyrogenicity, sterility and cytotoxicity, 
ratiﬁcation of the lack of temperate phages and conﬁrmation 
of the presence of the expected virion using transmission EM 
(Merabishvili et al. 2009; Pirnay et al. 2015).
The possible consequences and safety of phage therapy 
can be estimated from animal studies. Many successful 
preclinical studies in animals using phage therapy were per-
formed. The most frequently used animal model is a mouse 
model to establish an effective and advanced phage therapy 
system against infections caused by S. aureus or P. aeruginosa 
(Soothil 1992; Matsuzaki et al. 2003; Wang et al. 2006; Cap-
parelli et al. 2007; McVay et al. 2007; Watanabe et al. 2007; 
Vinodkumar et al. 2008; Debarbieux et al. 2010; Morello et 
al. 2011; Alemayehu et al. 2012). Some of these studies have 
shown phage therapy to be effective in the prevention of in-
fection in mice caused by antibiotic-resistant bacteria (Wang 
et al. 2006; Capparelli et al. 2007; Vinodkumar et al. 2008). 
There are some examples for phage therapy using another 
animal model such as guinea pig (Soothill 1994), rabbit (Wills 
et al. 2005), dog (Marza et al. 2006; Hawkins et al. 2010) or 
insect (Heo et al. 2009). The scientists developed methods for 
the intramuscular, intravenous, intraperitoneal, subcutaneous, 
intranasal and oral administration of phage preparations. Mo-
rello and co-workers (2011) showed that if they adapted the 
phage to the bacterial strain by repeated subculturing, phages 
were more effective in the treatment of lung infection in mice 
than the unadapted ones. Two research groups (Debarbieux 
et al. 2010; Alemayehu et al. 2012) used bioluminescent P. 
aeruginosa strain in mouse model to monitor in real-time the 
eradication of the infection by phages. They demonstrated a 
rapid killing of bacteria in phage-treated animals without the 
need of sacriﬁcing animals.
These animal studies have offered data that may be useful 
in rational planning of human clinical trials. To date, very few 
human clinical trials have been conducted according to West-
ern regulatory standards. Only four phase I and one phase 
II studies have been carried out and published. Two of the 
four phase I clinical trials targeted MDR Pseudomonas and 
methicillin-resistant S. aureus (MRSA) infections in venous 
leg ulcers (Intralytix) and burn patients (Belgian military) 
to evaluate the safety of phages (Kutter et al. 2010; Harper 
2012). The former was completed in 2008 at the Southwest 
Regional Wound Care Center in Lubbock, Texas. This study 
used “WPP-201”, a cocktail of eight phages prepared by 
the company Intralytix. The cocktail contained two phages 
active against S. aureus, ﬁve against P. aeruginosa and one 
against E. coli with a concentration of each at 1 × 109 PFU/
ml in phosphate-buffered saline solution. Twenty-one patients 
received phage cocktail and 18 served as control who received 
sterile phosphate-buffered saline. According to the results of 
this trial, no adverse effects were observed associated with the 
application of this multi-bacteriophage preparation (Rhoads et 
al. 2009). Another phase I safety trial of phage therapy against 
these two pathogens was carried out in 2009 in Belgium. The 
studied phage cocktail “BFC-1” consisting of three exclu-
sively lytic bacteriophages was produced by Merabishvili and 
co-workers (2009). No adverse effects were observed using 
the phage cocktail at a concentration of 1 ×  109 PFU/ml of 
each of the 3 phage types (Kutter et al. 2010).
The only Phase II clinical trial with a phage therapeutic 
agent was carried out by the British company Biocontrol Lim-
ited in 2007 (Wright et al. 2009). Following promising results 
in dogs suffering from chronic otitis caused by antibiotic-
resistant P. aeruginosa (Hawkins et al. 2010), they performed 
a double-blind placebo-controlled, randomized phase I/II 
clinical trial in humans for otitis. The used phage cocktail 
Biophage-PA consisted of six phages. Twenty-four patients 
with otitis externa were chosen whose infection was caused 
by Pseudomonas strains which were sensitive to at least one 
of these six phages. Half of the selected patients were treated 
topically with a single dose containing 105 phages of each 
of the 6 phage types. Another half of the selected patients 
received 10% glycerol phosphate-buffered saline diluent as 
placebo. The results of the study revealed that the presence 
of bacteria and the symptoms of the disease reduced in the 
treatment group but not in the placebo group. Complete bac-
terial eradication was not achieved, but this may be due to 
the relatively low titer of phages used in single dose. There 
were no remarkable side effects. The increasing number of all 
test phages in situ indicated that active therapy had occurred 
(Wright et al. 2009).
Based on the above-mentioned results, bacteriophages 
could play an important role in eliminating MDR bacteria in 
humans in the future and offer the most cost-effective alterna-
tive to antibiotics.
Listeria monocytogenes 
Out of the six members of the genus Listeria (L. monocy-
togenes, L. ivanovii, L. innocua, L. welshimeri, L. seeligeri 
and L. grayi), only two are considered pathogenic: L. mono-
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tion. The effect of the phage was strictly dose dependent. A 
smaller concentration of 1.5 ×  108 PFU/ml – when applied 
repeatedly – resulted in a 2-3 log decrease in the viable cell 
counts. A higher concentration of 3 ×  109 PFU/ml completely 
eradicated the infection. The presence of L. monocytogenes 
was monitored for three weeks and regrowth of the pathogenic 
strain did not occur (Carlton et al. 2005).
P100 was also tested against L. monocytogenes in catﬁsh 
ﬁllet. A dose of 2 × 107 PFU/g of phage P100 was necessary 
for a signiﬁcant reduction of the bacteria. This dose reduced 
L. monocytogenes counts by 1.5-2.3 log10/g. 2 ×  108 PFU/g 
was required to achieve a 2 log reduction. Although phage 
application initially reduced the L. monocytogenes counts, 
it did not inhibit growth during the ten day storage period. 
The same results were obtained at 4 °C and 10 °C (Soni et 
al. 2010).
The peptidoglycan cell wall of Gram-positive bacteria 
is easily accessible by phage-encoded endolysins from the 
outside. This has been demonstrated in a study, where en-
dolysin LysZ5 was expressed in E. coli and its lytic activity 
against L. monocytogenes has been tested in soy milk. The 
enzyme was able to reduce L. monocytogenes to undetectable 
levels. The reduction could be observed within 20 minutes 
and at refrigerated temperatures, showing that the enzyme 
retained its activity even at low storage temperatures (Zhang 
et al. 2012).
L. monocytogenes is able to form bioﬁlms which renders 
it extremely resistant to antibiotic-based disinfections. It is 
crucial to ﬁnd reliable and cheap procedures for preventing 
the formation or elimination of these bioﬁlms from metal 
surfaces, e.g., in food processing plants or hospitals. Phage 
P100 has been demonstrated to reduce L. monocytogenes lev-
els under bioﬁlm-forming conditions. It was effective against 
multiple serotypes of the bacteria, thus providing a promising 
tool to disrupt bioﬁlms (Soni and Nannapaneni 2010).
Salmonella species
The genus Salmonella contains two species: S. bongori and S. 
enterica. S. enterica is a Gram-negative rod-shaped faculta-
tive anaerobic bacterium. It is an important pathogen of both 
humans and animals and causes salmonellosis in humans, 
which is the second most common gastrointestinal infection 
in the European Union. Salmonella bacteria can colonize 
the intestinal tract of humans and farm animals, but it can 
also be found in wild birds, reptiles and insects. The disease 
is mainly transmitted with contaminated food. Although S. 
enterica has six subspecies, 99% of the human infections 
are caused by only one of the subspecies S. enterica subsp. 
enterica. The different serotypes of this subspecies account 
for different percent of the infections. The most common 
serotypes in the European Union in 2012 were S. enteriditis 
and S. typhimurium. Altogether, these two serovars were 
cytogenes which is able to infect animals and humans, and 
L. ivanovii infecting animals only. L. monocytogenes is a 
Gram-positive, rod-shaped, facultative anaerobic bacterium. 
It’s motile at room temperature, but does not synthesize 
ﬂagella at 37 °C. This human pathogenic microorganism is 
a food-borne pathogen and causes listeriosis. The infection 
can have the following symptoms: gastroenteritis, meningitis, 
neuro-encephalitis, chorioamnionitis, abortion and neonatal 
infections. Prominently in immunocompromised patients, the 
mortality rates are relatively high (Dworkin et al. 2006).
The bacteria from the genus Listeria are able to grow at 
low temperatures and high salt concentrations. These condi-
tions are used to preserve ready-to-eat (RTE) foods, thus 
making them ideal carriers of L. monocytogenes. According 
to the European Centre for Disease Prevention and Control 
(ECDC), listeriosis is an uncommon disease in the European 
Union, with an average of 1500 cases per year from 2008 till 
2012 (Table 1). The number of cases remained constant over 
the years, but with a high case-fatality ratio with a minimum 
of 12.1%. The disease infected particularly pregnant woman 
and elderly people over 65 years (Dworkin et al. 2006; ECDC 
2014).
Till this date, the genome sequences of 26 L. monocy-
togenes phages have been determined. All of the aforemen-
tioned phages belong to the order Caudovirales. Siphoviridae 
phages tend to have smaller genomes in the range of 35.64 
to 67.17 kb, while Myoviridae phages usually have genomes 
over a hundred kilobases from 131.38 to 138.04 kb. So far, 
no Podoviridae phage capable to infect L. monocytogenes has 
been characterized (Klumpp and Loessner 2013).
Multiple bacteriophages have been studied against L. 
monocytogenes infections. It is really important to conduct 
safety studies to show that application of single phages or 
cocktails of multiple phages is not harmful to individuals. In 
an oral toxicity study, mice were treated with approximately 2 
× 1012 phages per kilogram body weight per day for a ﬁve day 
period with bacteriophage P100. The phage preparation has 
been found safe and well-tolerated. No mortality, morbidity or 
histopathological changes related to the phage were observed 
(Carlton et al. 2005).
Phage P100 has been applied to a surface ripened cheese 
and found to completely eradicate L. monocytogenes infec-
Table 1. Numbers and rates of conﬁrmed listeriosis reported 
cases, EU, 2008-2012 (ECDC 2014).
2012 2011 2010 2009 2008
Number of con-
ﬁrmed cases
1642 1515 1663 1675 1425
Case rate per 
100000 population
0.37 0.31 0.35 0.35 0.30
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responsible for about 60% of the infections. The number 
of cases has a decreasing tendency, but the pathogen still 
accounts for ten thousands of infections annually (Table 2). 
Clinical manifestations of human salmonellosis range from 
subclinical gastroenteritis to severe bacteremia, meningitis, 
and other forms of extraintestinal infections. Poultry is one 
of the most prominent source of infections and therefore a 
successful treatment in animals could also reduce the number 
of human illnesses (Dworkin et al. 2006; ECDC 2014).
An oral toxicity study was performed, with bacteriophage 
wksl3 in mice. A single dose phage of high titer (1.1 ×  1011 
PFU/kg body weight) was administered to the animals. Dur-
ing the experimental period, no behavioral change or any 
physical symptom could be observed. No adverse effect on 
the organ level could be detected at the end of the experi-
ments. These results suggest that phage wksl3 is not toxic 
for the mice (Kang et al. 2013).
The same bacteriophage was used to treat chicken skin 
artiﬁcially infected with S. enteritidis. A signiﬁcant 3 log 
decrease in the bacterial counts could be observed after 24 
hours at 8 °C. Some growth still occurred on the second day, 
but no signiﬁcant growth was observable after it. After the 
experiment forty-eight cells were recovered and tested for 
resistance against phage wksl3. All of the tested bacteria 
remained susceptible to the phage (Kang et al. 2013).
In a previous study, the activity of phage Φ1 against 
S. enterica serovar paratyphi B was evaluated. Mice were 
injected with a lethal dose of bacteria (107 CFU/animal) 
and immediately injected with phage Φ1. While all animals 
in the control group died within 48 hours, all of the phage 
treated mice survived. The difference between the two groups 
could also be observed at the organ levels. The bacterial load 
of blood and two of the most heavily infected organs (liver 
and gastrointestinal tract) were also compared. No bacteria 
from the phage-treated group could be isolated, whereas the 
control group displayed high bacterial loads (>106 CFU/ml 
in the blood, >106 CFU/g in the gastrointestinal tract). How-
ever, a successful therapy should be effective when delayed 
compared to the infection. Therefore mice were infected 
with a sublethal dose (105 CFU/animal) of the pathogen and 
treated only two weeks later. Phage Φ1 proved to be success-
ful in disinfecting the animals even when the treatment was 
delayed. A Φ1 phage-resistant strain was isolated from the 
phage-susceptible strain. This new strain, however, could not 
infect mice and was cleared from the systems of the animals 
within 4-7 days. Mice immunized with this strain showed 
resistance against infection with the pathogenic strain (Cap-
parelli et al. 2010).
Since poultry is one of the most prominent infection 
sources, a successful treatment in these animals could also 
reduce the number of human illnesses. The efﬁciency of three 
phages against three S. enteritidis serotypes in commercially 
available chickens was evaluated (Atterbury et al. 2007). It 
has been found that high concentration of the phages (1011 
PFU) reduced the bacterial number of serotypes S. enteritidis 
and S. typhimurium by more than 2 log. The number of se-
rotype S. hadar was unaltered in these experiments, however 
in vitro the viable counts of these bacteria were signiﬁcantly 
reduced. 
The intestinal tract of animals is a very complex environ-
ment. In this case, a signiﬁcantly higher number of phages is 
required for successful reduction of bacterial counts. Bacte-
riophage-insensitive mutants could recolonize the intestinal 
tract after the initial reduction of the bacterial numbers. 
However, administration of phages just prior to slaughter 
could still result in a signiﬁcant reduction of bacterial loads 
(Atterbury et al. 2007).
Salmonella species are able to colonize solid surfaces 
(e.g., stainless steel, glass) similarly to L. monocytogenes. 
Two phage cocktails SalmoFresh™ and SalmoLyse™ were 
tested for their ability to reduce Salmonella contamination on 
the aforementioned surfaces. SalmoFresh™ was able to lyse 
S. kentucky and S. brandenburg and therefore, signiﬁcantly 
reduced bacterial counts (>99% reduction). This ﬁnding is in 
accordance with previous spot test assays, where these two 
strains were found susceptible to the phage cocktail. Salmo-
Fresh™ wasn’t able to lyse S. paratyphi B. Two phages from 
the cocktail were substituted with ones that were also able 
to lyse S. paratyphi B in vitro, thereby constructing Salmo-
Lyse™. This new cocktail was effective against S. paratyphi 
B as well. With these experiments the authors showed that 
updating phage cocktails for following changes in bacterial 
populations and bacterial resistance is technically feasible 
(Woolston et al. 2013).
Currently, phage preparations against L. monocytogenes 
(Listshield™) and S. enterica (SalmoFresh™) are commer-
cially available in the USA. Listshield™ is approved GRAS 
for direct application to ﬁsh and shellﬁsh (including smoked 
varieties, like smoked salmon), fresh and processed fruits, 
fresh and processed vegetables and dairy products (including 
cheese) (GRN No. 528). SalmoFresh™ is also in GRAS status 
for direct application onto poultry, ﬁsh and shellﬁsh, fresh and 
processed fruits and vegetables (GRN No. 435).
Table 2. Number and rates of conﬁrmed salmonellosis cases, EU, 
2008-2012 (ECDC 2014).
2012 2011 2010 2009 2008
Number of con-
ﬁrmed cases
91029 96682 101589 110179 134581
Case rate per 
100000 popula-
tion
21.82 20.75 21.78 23.94 29.61
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Conclusion
Applicability of phages against pathogenic bacteria has been 
recognized one hundred years ago but phage therapy as an 
antibacterial treatment retrograded due to the appearance of 
antibiotics. Upon the emergence and fast spread of multidrug-
resistance, nowadays, development of novel antibiotics is 
not feasible and alternative antimicrobial approaches should 
be discovered and applied. Phage therapy has many beneﬁts 
over antibiotics, represents a green solution for elimination 
of harmful bacterial infections even in those cases when 
antibiotics are ineffective. This has been realized in the last 
decades and the innovative research on phage therapy and en-
zybiotics was revitalized. A decade ago, it was an outstanding 
milestone, that FDA has approved the application of phages 
as food additives. However, medical application of phages 
still requires further systematic studies, carefully performed 
clinical trials and – very importantly – well-deﬁned regulatory 
rules. Fortunately, it was understood by the decision makers 
and research on phage therapy is encouraged in most parts 
of the world. These facts and events indicate that widespread 
applications of phage-based antimicrobial agents might be 
expected in the future.  
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